Part 1. Gefitinib and Erlotinib for Non-Small Cell Lung Cancer
Technology Assessment
The technology assessment program
at the Agency for Healthcare Research and Quality (AHRQ) provides technology
assessments for the Centers for Medicare & Medicaid Services (CMS). These
technology assessments are used by CMS to inform its national coverage
decisions for the Medicare program as well as provide information to Medicare
carriers.
AHRQ's technology assessment program uses state-of-the-art methodologies for assessing the clinical utility of medical interventions. Technology assessments are based on a systematic review of the literature, along with appropriate qualitative and quantitative methods of synthesizing data from multiple studies.
Select for PDF Version (350 KB). PDF Help.
Contents
Glossary
Introduction
Methods
Results
Adverse Effects/Harms
Discussion
References
Included Articles
Excluded Articles
Appendixes
Prepared for AHRQ under Contract No. 290-02-0025. By Michael
J. Kelley, M.D., and Douglas C. McCrory, M.D., M.H.S., Duke Evidence-based
Practice Center, Center for Clinical Health Policy Research.
Current as of November 2005
Internet Citation:
Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy. Part 1, Gefitinib and Erlotinib for Non-Small Cell Lung Cancer. Technology Assessment. October 2005. Rockville, MD: Agency for Healthcare Research and Quality. http://www.ahrq.gov/clinic/ta/nonsmall/